Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Neurocrine Biosciences (NBIX) over the last 15 years, with Q4 2025 value amounting to $4.6 billion.

  • Neurocrine Biosciences' Liabilities and Shareholders Equity rose 2454.62% to $4.6 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $16.5 billion, marking a year-over-year increase of 1741.56%. This contributed to the annual value of $4.6 billion for FY2025, which is 2454.62% up from last year.
  • According to the latest figures from Q4 2025, Neurocrine Biosciences' Liabilities and Shareholders Equity is $4.6 billion, which was up 2454.62% from $4.3 billion recorded in Q3 2025.
  • Over the past 5 years, Neurocrine Biosciences' Liabilities and Shareholders Equity peaked at $4.6 billion during Q4 2025, and registered a low of $1.8 billion during Q1 2021.
  • In the last 4 years, Neurocrine Biosciences' Liabilities and Shareholders Equity had a median value of $3.3 billion in 2024 and averaged $3.2 billion.
  • As far as peak fluctuations go, Neurocrine Biosciences' Liabilities and Shareholders Equity skyrocketed by 4714.81% in 2024, and later soared by 620.03% in 2025.
  • Over the past 4 years, Neurocrine Biosciences' Liabilities and Shareholders Equity (Quarter) stood at $2.0 billion in 2021, then surged by 61.18% to $3.3 billion in 2023, then grew by 14.37% to $3.7 billion in 2024, then grew by 24.55% to $4.6 billion in 2025.
  • Its Liabilities and Shareholders Equity was $4.6 billion in Q4 2025, compared to $4.3 billion in Q3 2025 and $3.9 billion in Q2 2025.